The larger sizes cut down on the number of vials needed for reconstitution. The Food and Drug Administration (FDA) has approved additional vial sizes of Zemaira (alpha1-proteinase inhibitor [human]; ...

The high prices of chemotherapy drugs and the financial burden they pose on public programs, private insurers and patients is a major source of concern. However, addressing this problem through ...

Current lecanemab vial sizes lead to 5.8% waste, a study suggested. An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save Medicare ...

The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug Administration ...

Pill bottles Vial preparation sizes can be optimized to reduce drug wastage, reduce costs. HealthDay News — Pharmaceutical vial fill volumes can be optimized to reduce drug wastage when dosing is ...

On March 1, 2016, we published an article in the BMJ showing how in the US nearly $3 billion will be spent on discarded cancer drugs this year because companies package drugs in vials that contain too ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims. About 6% of Leqembi (lecanemab ...

In a blogpost on Health Affairs, 2 economists have challenged the claim made by researchers that packaging expensive, patented chemotherapy drugs into multiple vial sizes could reduce wastage and in ...

--ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commercial ...

Medicare could waste up to $605 million per year on the controversial Alzheimer's drug aducanumab if it is eventually approved for widespread use because it is supplied in vials containing fixed doses ...

The high prices of many patented pharmaceuticals, especially chemotherapy drugs, pose substantial challenges to the budgets of public programs, private insurers, and patients and their families.